Ardent Health Partners (ARDT) Q3 2024 Earnings Report

Ardent Health Partners LLC reported QQ3 2024 revenue of $1.450 billion, up 5.2% year over year but down 1.4% quarter over quarter, reflecting a resilient top line against a backdrop of margin pressure. Gross profit totaled $636.0 million with a gross margin of 43.9%, yet year-over-year gross profit declined roughly 53.8% and quarter-over-quarter fell about 47.5%, signaling ongoing cost and mix challenges even as volumes remained supportive. EBITDA stood at $108.5 million (margin ~7.5%), and operating income was $57.1 million (operating margin ~3.94%), yielding net income of $26.3 million and basic EPS of $0.19 for QQ3 2024.

The balance sheet shows a solid asset base of about $4.80 billion, with cash and equivalents of $563.1 million and total debt of approximately $2.252 billion, resulting in a net debt position of around $1.689 billion. Free cash flow generated in the quarter was $48.7 million, contributed by $92.2 million of operating cash flow, underscoring ongoing cash generation to support deleveraging, capital allocation, and potential strategic initiatives.

While the company demonstrates robust liquidity and cash generation, gross margin deterioration and modest profitability metrics highlight margin compression risks. Management commentary is not included in the supplied data, so explicit guidance or qualitative signals from QQ3 2024 earnings calls are not available. The investment thesis hinges on Ardent’s ability to improve margin discipline, optimize the cost base, and execute growth in outpatient and centralized services while maintaining a balanced capitalization and strong cash generation.